Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of Automated...

Top-Five Global Pharmaceutical Company Names NewCardio as its Provider of
Automated Thorough QT Solution
Selects NewCardio's Proprietary Technology for All Fully Automated Thorough QT
Studies

SANTA CLARA, Calif., July 30 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC
Bulletin Board: NWCI) a cardiac diagnostic and services company, today
announced that a top-five pharmaceutical company has named NewCardio's
QTinno(TM) software suite, NewCardio's first commercial product, as the
technology that will be used in all of its fully automated Thorough QT (TQT)
studies.

The pharmaceutical company evaluated several automated cardiac safety
solutions before choosing QTinno(TM) as its automated solution moving forward.
As part of this evaluation, a blinded TQT dataset was provided for processing
by the automated solutions. The automated results were then un-blinded by the
pharmaceutical company and compared to the original core lab results. The
pharmaceutical company determined that NewCardio's solution demonstrated the
highest consistency and lowest variability in relation to the original core
lab results. After reviewing NewCardio's underlying platform technology, the
pharmaceutical company determined that QTinno(TM) was the solution it will
utilize to begin replacing the semi-automated methodology currently utilized
by its preferred ECG core labs. At recent industry conferences, a number of
pharmaceutical companies have expressed a strong desire to transition to fully
automated methods in an effort to reduce human error, minimize intrinsic
variability and increase efficiency.

Going forward, all TQT study requests for proposals (RFPs) issued by the
pharmaceutical company that will require a fully automated component will
require the use of NewCardio's QTinno(TM) by its preferred ECG core labs. It
is anticipated that this pharmaceutical company will conduct its first
clinical trial using fully automated readings by the end of the year and will
increasingly utilize fully automated results in its TQT studies.

"NewCardio is excited to work with a major pharmaceutical company and we
believe this is the clearest signal yet of the impending transition to fully
automated cardiac testing in drug development as sponsors look for ways to
improve quality while simultaneously reducing expenses," said Vincent Renz,
NewCardio's President and Chief Operating Officer. "This global pharmaceutical
leader is an early adopter, and this announcement demonstrates their
commitment to quality, safety and the use of new technologies to drive
innovation."

NewCardio's innovative 3D ECG platform technology dramatically improves the
accuracy and significantly increases the diagnostic value of the standard
12-lead electrocardiogram (ECG). NewCardio's lead product is QTinno(TM), a
software suite that provides an automated, comprehensive analysis of QT
intervals and other ECG-based cardiac safety for the pharmaceutical industry
and drug regulators. The Company believes that its QTinno(TM), software-based,
analytical technology is the industry's first solution for the reliable
automated analysis of ECGs used to determine cardiac toxicity during drug
development.

About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the
development of a proprietary platform technology to provide higher accuracy
to, and increase the value of, the standard 12-lead electrocardiogram (ECG).
NewCardio's development-stage software and hardware products and services are
intended to improve the diagnosis and monitoring of cardiovascular disease
(CVD), as well as cardiac safety assessment of drugs under development.
NewCardio's three-dimensional ECG platform is designed to reduce the time and
expense involved in assessing cardiac status while increasing the ability to
diagnose clinically significant conditions which were previously difficult to
detect. For more information, visit www.newcardio.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking
statements include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any other
statements relating to our future activities or other future events or
conditions. These statements are based on current expectations, estimates and
projections about our business based on currently available information and
assumptions made by management. Although we believe that the assumptions on
which the forward-looking statements contained herein are based are
reasonable, any of those assumptions could prove to be inaccurate given the
inherent uncertainties as to the occurrence or nonoccurrence of future events.
These statements are not guarantees of future performance and involve risks
and uncertainties that are difficult to predict. Therefore, actual outcomes
and results may, and are likely to, differ materially from what is expressed
or forecasted in the forward-looking statements due to numerous factors,
including the potential risks and uncertainties set forth in Item 1A of our
Annual Report on Form 10-K for the year ended December 31, 2008 and relate to
our business plan, our business strategy, development of our proprietary
technology platform and our products, timing of such development, timing and
results of clinical trials, level and timing of FDA regulatory clearance or
review, market acceptance of our products, protection of our intellectual
property, implementation of our strategic, operating and people initiatives,
benefits to be derived from personnel and directors, ability to commercialize
our products, our assumptions regarding cash flow from operations and cash
on-hand, the amount and timing of operating costs and capital expenditures
relating to the expansion of our business, operations and infrastructure,
implementation of marketing programs, our key agreements and strategic
alliances, our ability to obtain additional capital as, and when, needed, and
on acceptable terms and general economic conditions specific to our industry,
any of which could impact sales, costs and expenses and/or planned strategies
and timing. Information concerning factors that could cause our actual results
to differ materially from these forward-looking statements can be found in our
periodic reports filed with the Securities and Exchange Commission. We assume
no obligation to, and do not currently intend to, update these forward-looking
statements.
Investor Contact:
Hayden IR
Jeff Stanlis, Partner and VP of Communications
(602) 476-1821
jeff@haydenir.com

SOURCE NewCardio, Inc.

Jeff Stanlis, Partner and VP of Communications of Hayden IR, +1-602-476-1821,
jeff@haydenir.com, for NewCardio, Inc.